Try our Advanced Search for more refined results
Life Sciences - March, 2011
225 articles
- J&J Judgment In Stent Patent Suit Climbs To $593M
- Cephalon Investor Sues Over $5.7B Valeant Bid Rebuff
- FDA Panel Calls For More Study On Food Dyes, ADHD
- Actavis Pays $10M To Exit Kentucky Medicaid Suit
- Judge Lets Yaz Counterclaims Against Bayer Stand
- Swisslog Prevails In McKesson Drug Dispenser IP Suit
- WilmerHale Snatches Howrey, Munger Tolles IP Attys
- Aventis Settles Suit Over Allegra Patent
- Judge Nixes Dismissal Bid In Thalomid Antitrust Suit
- Biolitec Laser Doesn't Infringe AMS Patent: Judge
- Ex-Yelp Sales Worker Launches OT Class Action
- Medtronic Didn't Infringe BSC Defibrillator IP: Judge
- GSK Gets $3.5M Verdict In Norvir Antitrust Case
- FDA Weighs Testimony On Health Risks Of Food Dyes
- CDC Probes Bacteria Outbreak From Contaminated IVs
- DC Resident's FCA Claims Killed In Vioxx Fight
- Sanofi Can't Nix Shareholder Suit Over Zimulti
- Novartis, Elan Sue IPC Over Generic Focalin XR
- Generics Makers Ask High Court For State Law Shield
- Pronova, Apotex Strike Deal Over Generic Lovaza
- Paxil Suits Remanded To State Court, To GSK's Chagrin
- Sullivan & Cromwell Reps Valeant In $5.7B Cephalon Bid
- Lannett Loses Bid To Enforce Celgene Oral Agreement
- Elan, Abbott Settle With Lupin Over Generic TriCor
- J&J Recalls Tylenol Products Amid Odor Concerns
- SEC Says FDA Chemist Made $3.6M In Insider Trading
- Fed. Circ. Fines Sun, Caraco Attys In Eloxatin IP Case
- Pfizer Subsidiary Recalls Mislabeled Drugs
- Apotex Must Return $28M Award To Servier: UK Court
- Judge Rules Generic Drug Infringes Dermalogix Patent
- Chattem To License LecTec Patch Patents For $3.6M
- FTC OKs $76M Astellas-Maxygen Protein Program Deal
- High Court Kills County's Drug Price Class Action
- Cephalon Loses Bid For Quick Win In Marketing Suit
- Merck To Pay $4.2M To End Wis. Medicaid Fight
- Pfizer Beats False Marking Claims
- High Court Seeks US' View In Prandin Use Code Case
- Drugstore.com Investor Fights $409M Walgreen Deal
- Fed. Circ. Revives Watson Challenge Of Seasonique IP
- CORRECTED: FTC OKs Quest's $740M Buyout Of Athena
- Class Rep Pushes To Kill Deal Over Chemo Drug Sales
- Purdue Sues Watson Over Generic OxyContin
- Medtronic Unit Must Face Antitrust Claims: Judge
- Animal Health Investor Contests $251M Lextron Deal
- False Marking Law Found Constitutional In GSK Case
- US To Take False Marking Law To Fed. Circ.
- Wyeth Takes $58M Loss In Hormone Case To High Court
- Howmedica Asks High Court To Weigh Polymer IP Case
- 2nd Circ. Affirms Suntrust Win In Defamation Suit
- Cephalon Wins IP Suit Over Watson's Generic Fentora
- Haynes & Boone Adds Ex-Howrey Antitrust Atty
- Par Sues UCB Over Generic Keppra
- Drug Sales Rep Sues Eisai Over OT Pay
- An Adverse Event For Statistical Significance
- $8.9M Nuvelo Class Action Deal Wins Preliminary OK
- ITC Takes Up 337 Probe Of Merck's NuvaRing
- Point Blank CEO Hit With Lawsuit Over SEC Deal
- Medtronic Unit Settles Faulty Spinal Implant Suit
- J&J Unit Yanks 360K Surgical Drain Products
- Solvay Wants Firms, Expert Removed In AndroGel Suit
- Fed. Circ. Nixes Apotex Appeal In Taxotere IP Fight
- Abbott Strikes Deal In Antitrust Battle Over HIV Drugs
- Medtronic, NuVasive Spinal Surgery IP Suit Continues
- 4 Views On Medical Device Preemption
- Jones Day Reps P&G in Joint Venture With Teva
- Sidley, Weil Rep Walgreen In $409M Drugstore.com Buy
- J&J Unit Downplayed Risperdal's Diabetes Link: Jury
- Terumo To Pay $35M Over Heart Device Violations
- Ex-GSK Atty Gets Indictment Over Wellbutrin Tossed
- Abbott, WARF End Zemplar Patent Suit Against Anchen
- FTC Blesses Daiichi Sankyo's $805M Plexxikon Buy
- HIG Picks Up Teleflex's Marine Biz For $122M
- Celera Investor Sues To Block $344M Quest Deal
- Utah University Sues Planck, MIT Over RNA Patents
- Takeda Sues Apotex Over Generic Actos
- Abbott Files New Simcor Patent Suit Against Teva
- Matrixx Opens Door For Plaintiffs, But Only A Crack
- Pfizer Unit To Exit Ch. 11 With $265M Asbestos Deal
- FTC Warns Miss. Lawmakers Over Drug Manager Bill
- Actavis Agrees To Hold Off On Generic Nuvigil
- BSC Can't Shake Contract Claim In Stent Patent Suit
- Sanofi, Merck Drop Animal Health Joint Venture
- Actonel Makers Launch 2nd Suit Over Mylan Generic
- Zuckerman Taps Buc & Beardsley FDA Pros
- Indicted GSK Atty Says Prosecutors Misled Grand Jury
- MetaMorphix Seeks To Convert Case To Ch. 7
- Judge Asked To Toss Troutman Atty's Real Estate Suit
- Angiotech Seeks US Approval Of Canada Restructuring
- Female Bayer Workers Launch $100M Sex Bias Suit
- High Court Won't Hear Mylan IP Fight Over Benicar
- Milbank Technology Head Departs For Dewey
- Camera-Pill Maker Triumphs In Endoscopy Patent Suit
- Morrison Ruling Doesn't Bar Elan ADR Suit: Judge
- 5 Marketing Lessons From Howrey's Graveside
- Duane Reade Escapes $7M Kasowitz Legal Fee Spat
- 1st Circ. Nixes NeuroMetrix Device Securities Suit
- Mylan Pushes FDA To Rule On Ranbaxy's Lipitor ANDA
- Recall: Prevent, Manage, Mitigate And Survive
- Medco Sued Over CalPERS Bribery
- Coudert Settles Bard Unit's $25M Malpractice Claim
- Calif. Joins Relator's Kickback Suit V. Bristol-Myers
- Convicted Trader Protests SEC Penalty In 2nd Circ.
- Judge Backs $2.8M Penalty In Insider Trading Suit
- US Sues Teva Over Generic HIV Drug
- SigmaPharm Appeals Skelaxin Antitrust, Contract Suit
- CDC Proposes New HIV Test Timeline For Organ Donors
- Nycomed Faces IP Suit Over Solaraze Gel
- Mich. Can't Sue Merck Over Vioxx, Appeals Court Says
- Orchid Can't Nix Roche Boniva Patent
- Labeling Gaffe Sparks Mylan Drug Recall In Canada
- FDA Panel Pushes Menthol Cigarette Ban
- Shearman Reps Quest Diagnostics In $344M Celera Buy
- Bayer Birth Control Patents Mostly Survive UK Suit
- FDA Head Takes $4.3B Budget Defense To Senate
- ITC Launches 337 Case Over Lilly's Gemzar Patent
- 1st Circ. Nixes FirstBank Appeal In Merger Fraud Suit
- Pfizer Unit Recalls Pain Drug Embeda
- Apotex Doesn't Infringe Provigil Patent, Judge Says
- Braintree Hits Amrutham With Laxative Patent Suit
- Teva Exits Astellas Patent Suit Over Cancer Drug
- Tekmira Claims Alnylam Stole Gene Therapy Secrets
- Baxter Pockets Partial Costs In ERISA Win
- Triad Halts Production Of Pads Tied To Child's Death
- Premier Wins Bid To Arbitrate Rival's Antitrust Suit
- Endo Sues Mylan Over Generic Lidoderm Patch
- Cephalon Tries To Nix Approval For Generic Fentora
- Alnylam, German Group Settle RNA Patent App Case
- Gilead, Roche Sue To Block Generic Tamiflu
- IP Official Recommends Stronger Enforcement Plan
- Reviving Time-Barred Actions Via Legislation
- Merger Negotiations Can Stay Private — Usually
- Rite Aid Managers Take OT Actions To 3rd Circ.
- AstraZeneca Says SC Seroquel Suit Is Money Grab
- Ulmer & Berne Adds Ex-Dinsmore & Shohl Litigator
- Stragent Slaps Infineon, Others With Tech Patent Suit
- Fed. Circ. Won't Revisit Abraxis Loss In Naropin Suit
- Ex-Exactech Director Avoids Prison In Kickback Case
- Ropes & Gray Lures Life Sciences Atty From Goodwin
- White House Moves To Combine Trade Agencies
- Watson Wins Invalidity Ruling On 2 Fentora Patents
- Aventis, Sandoz Drop Swords In Taxotere Patent Suit
- 2nd Circ. Kills B&L Indemnity Bid, Not Defense Claim
- Minn. Pharmacy Class Suit Wrongly Remanded: 8th Circ.
- FDA Chief Backs $4.3B Budget In House Hearing
- MoFo Snags M&A Pro From Cooley For Calif. Office
- A Shot In The Arm For Section 2 Enforcement
- Patients Sue Genzyme Over Fabrazyme Rationing
- J&J Unit Agrees To Stop Making Drugs At Pa. Plant
- Ex-KV CEO Gets 1 Month, $1M Fine For False Drug Marks
- Judge Delays Approval Of SEC Deal With Body Armor Co.
- EU Embryo Patent Ban Covers Stem Cells: Court Adviser
- Becton Asks Fed. Circ. To Chuck $5M Syringe IP Loss
- Merchant & Gould Adds Hatch-Waxman Guru To IP Team
- AstraZeneca Seeks To Block Ex-Consultant's Testimony
- AstraZeneca To Pay $69M To States Over Seroquel
- 2010 In Review: Canadian Competition And Marketing
- Judge Certifies Mass. Class In CVS False Ad Suit
- Generics Maker Sues 3M In Skin Cream Row
- Gaims Weil Can't Ditch Wiretap Claims: Calif. Court
- American Capital Can't Nix Insurers' Heparin Suit
- Corporate Vet Joins Dentsply As General Counsel
- Allergan, Rivals Debate Competition Claims' Validity
- Abbott Can't Escape Suit Over Insects In Baby Formula
- Child Deaths Not Linked To Vaccines: Japan Drug Panel
- Noteholders To Buy Metamorphix Assets For $6M
- BSC, St. Jude Reach Deal Over Sales Exec Noncompete
- Ex-Best Medical Workers Slip Cancer Therapy IP Suit
- Mass. Targets Fund Over Use Of Expert Network Info
- Fla. Judge Backs Contract For Prescription Program
- Latham Reps Catalyst In $525M Walgreen Unit Buy
- Arrow, J&J Liability Claims Preempted: 11th Circ.
- FDA Warns Of Risks To Babies From HIV Drug Kaletra
- Fed. Circ. Kills Mylan's Prilosec Antitrust Claims
- FTC Blesses GTCR's $675M Purchase Of Sterigenics
- GSK Sales Reps Seek 9th Circ. Rehearing On OT Status
- Fueling The BPCI Debate
- Drugmakers Beat Price-Fixing Claims In Ca. Court
- Caremark Can't Ditch Contract Claims In Coventry Suit
- Gibson Dunn Reps Accuray In $277M Radiotherapy Deal
- Generics Co. Asks Fed. Circ. To Revive Fortican Claims
- Bovie, Medtronic Settle IP Suit Over Surgical Device
- Watson, Orchid Defenses Live In Generic Azilect Row
- AstraZeneca, Mylan Spar Over Prilosec Suit Dismissal
- High Court Denies Cert In Biopsy Tool Patent Suit
- MoFo Reps Terumo In $2.6B Gambro Unit Deal
- Japan Halts Pfizer, Sanofi Pediatric Vaccines
- Kirkland & Ellis Nabs IP Veteran From Jones Day
- Maximizing Your Chance At Federal Dollars
- Top Court Refuses To Hear Pay-For-Delay Challenge
- Gov'ts Win Cert. In McKesson Price-Rigging Suit
- Mylan, Others Hit With Class Action Over Painkillers
- Blackstone Sues Taro For $6M In Unpaid Merger Fees
- Drug Supply Co. Fraud Suit Referred To Mediation
- Cephalon Bid For Apotex Docs Denied In Provigil Suit
- Occlutech Implants Don't Violate IP: Swedish Court
- Sterilizer Co. To Pay $20M In Medical Device Action
- Ex-Cyberonics CEO Defies Options Reports In 2nd Circ.
- Howrey Attys Flee To Dewey & LeBoeuf, Perkins Coie
- Merck Must Face Unjust Firing Suit, 1st Circ. Rules
- UnitedHealth Hit With ERISA Class Action
- Spain Hits Hair Care Cos. With $71M Cartel Fine
- FDA To Up Topamax Warning Over Birth Defect Data
- Cigna Worker Launches $100M Sex Bias Action
- Immunizing Vaccine Manufacturers From State Claims
- Allergan Tries To Nix Breast Implant Marking Suit
- Merck Settles Trade Secrets Row Over Software
- J&J's Ethicon Unit Reveals Surgical Suture Recall
- Fed. Circ. Invalidates Crafco Patent For Obviousness
- McKesson Fights $212M Ariz. Fine Over Drug Prices
- Fulbright Picks Up 2 Litigators For LA Office
- Neuralstem Calls StemCells Patents 'Unenforceable'
- Insurers Freed From Tissue Donation Coverage Suit
- Shareholder Seeks To Halt $1.2B Clinical Data Sale
- FDA Cracks Down On Unapproved Cold, Cough Drugs
- Merck, Teva End Cancidas Patent Fight
- Astellas Sued Over Efforts To Block Generic Prograf
- Pay-For-Delay Deals Stay Under Wraps In Cephalon Suit
- FTC Gives Green Light To $1.25B CVS-Universal Deal
- KemPharm Hits Shire With Antitrust Counterclaims
- Allergan's Acadia Securities Sales Spark SEC Subpoenas
- Simpson Reps Daiichi Sankyo In $805M Plexxikon Buy
- Howrey Partners Defect To MoFo, Kirkland, Others
- GenMark Drops Suit Over Caliper Microfluidics Patents
- ClearCorrect Faces IP, Competition Suits Over Braces
- Beware Of GSA's Price Reductions Clause